JP2024531728A5 - - Google Patents

Info

Publication number
JP2024531728A5
JP2024531728A5 JP2024516476A JP2024516476A JP2024531728A5 JP 2024531728 A5 JP2024531728 A5 JP 2024531728A5 JP 2024516476 A JP2024516476 A JP 2024516476A JP 2024516476 A JP2024516476 A JP 2024516476A JP 2024531728 A5 JP2024531728 A5 JP 2024531728A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
nucleotide sequence
seq
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531728A (ja
Filing date
Publication date
Priority claimed from GBGB2113104.0A external-priority patent/GB202113104D0/en
Priority claimed from GBGB2207239.1A external-priority patent/GB202207239D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/075355 external-priority patent/WO2023041508A2/en
Publication of JP2024531728A publication Critical patent/JP2024531728A/ja
Publication of JP2024531728A5 publication Critical patent/JP2024531728A5/ja
Pending legal-status Critical Current

Links

JP2024516476A 2021-09-14 2022-09-13 心血管疾患の処置 Pending JP2024531728A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2113104.0 2021-09-14
GBGB2113104.0A GB202113104D0 (en) 2021-09-14 2021-09-14 Antagonist of pcsk9
GB2207239.1 2022-05-18
GBGB2207239.1A GB202207239D0 (en) 2022-05-18 2022-05-18 Treatment of cardiovascular disease 2
PCT/EP2022/075355 WO2023041508A2 (en) 2021-09-14 2022-09-13 Treatment of cardiovascular disease

Publications (2)

Publication Number Publication Date
JP2024531728A JP2024531728A (ja) 2024-08-29
JP2024531728A5 true JP2024531728A5 (cg-RX-API-DMAC7.html) 2025-07-23

Family

ID=83691543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516476A Pending JP2024531728A (ja) 2021-09-14 2022-09-13 心血管疾患の処置

Country Status (5)

Country Link
US (1) US20250283076A1 (cg-RX-API-DMAC7.html)
EP (1) EP4402263A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024531728A (cg-RX-API-DMAC7.html)
CA (1) CA3229020A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023041508A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
TW202345865A (zh) * 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
EP4680740A1 (en) * 2023-03-14 2026-01-21 Argonaute Rna Limited Conjugate comprising a double stranded rna molecule linked to a single stranded dna molecule
AU2024265748A1 (en) * 2023-05-04 2025-10-23 Argonaute RNA Limited Dual silencing
WO2024245151A1 (zh) * 2023-05-26 2024-12-05 维亚臻生物技术(苏州)有限公司 一种用于代谢疾病的双链核苷酸化合物及其应用
TW202515586A (zh) * 2023-08-09 2025-04-16 大陸商北京福元醫藥股份有限公司 抑制DGAT2基因表達的siRNA、siRNA綴合物或其前藥和藥物組合物及用途
CN120035670A (zh) * 2023-08-23 2025-05-23 云合智药(苏州)生物科技有限公司 用于抑制二酰甘油-O-酰基转移酶2表达的RNAi剂及其应用
TW202540420A (zh) * 2023-11-15 2025-10-16 大陸商北京加科瑞康醫藥科技有限公司 用於抑制LPA的基因表現的siRNA,含其的組合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2219517T3 (es) 2000-03-03 2004-12-01 Glaxosmithkline Biologicals S.A. Vacuna para el tratamiento de la aterosclerosis.
GB0121171D0 (en) 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
GB0305794D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP1675949A2 (en) 2003-10-23 2006-07-05 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8067572B2 (en) * 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
EP2505646A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
CA2658183A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
WO2010141511A2 (en) * 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
WO2012058693A2 (en) * 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
BR112015013105B1 (pt) * 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
EP3656386A1 (en) 2013-06-21 2020-05-27 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
JOP20160211B1 (ar) 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
US11065216B2 (en) 2016-11-16 2021-07-20 Purdue Research Foundation Compositions and methods for regulating body weight and metabolic syndromes
CN119120476A (zh) 2017-11-13 2024-12-13 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸
AU2019380628B2 (en) * 2018-11-13 2024-10-31 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of LPA in a cell
CN114072503A (zh) * 2019-07-02 2022-02-18 阿尔戈诺特Rna有限公司 载脂蛋白b拮抗剂
JP7827623B2 (ja) * 2019-12-09 2026-03-10 アムジエン・インコーポレーテツド LPA発現を阻害するためのRNAiコンストラクト及び方法
US20230183694A1 (en) * 2020-03-16 2023-06-15 Argonaute RNA Limited Antagonist of pcsk9

Similar Documents

Publication Publication Date Title
ES2546450T3 (es) Método para amplificar y detectar un ácido nucleico usando ácido nucleico bicatenario como molde
JP2024500036A5 (cg-RX-API-DMAC7.html)
EP2407558A1 (en) Methods for the detection of a single- or double-stranded nucleic acid molecule
CA2785451C (en) Molecule for treating an inflammatory disorder
JP6997784B2 (ja) 核酸の増幅方法および該方法を実施するためのキット
JP2023519140A5 (cg-RX-API-DMAC7.html)
JP2009514877A5 (cg-RX-API-DMAC7.html)
PT1527176E (pt) Novas formas de muléculas de arn de interferência
US9944928B2 (en) Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions
JP2014527401A5 (cg-RX-API-DMAC7.html)
JP2005517436A5 (cg-RX-API-DMAC7.html)
CN105008533A (zh) 嵌合单链反义多核苷酸和双链反义试剂
WO2019196887A1 (zh) 一种新型小激活rna
JPH06510669A (ja) 核酸伸長検定
JP7033591B2 (ja) 治療用オリゴヌクレオチドの捕捉および検出
CN103290009A (zh) 具有促进iNOS的分解的NO产生活性的正义寡核苷酸以及iNOS产生量的抑制方法
WO2023041508A3 (en) Treatment of cardiovascular disease
JP2003517283A (ja) プライマーペアの増幅及び配列決定並びにそれらの使用
WO2024196779A2 (en) Optimized antisense sequences that enhance targeted rna editing by adar proteins
JP2022537987A5 (cg-RX-API-DMAC7.html)
JP2026074094A (ja) Fubp1発現を調節するための増強されたオリゴヌクレオチド
JP2006521824A5 (cg-RX-API-DMAC7.html)
Hey et al. Nonenzymatic oligomerization of ribonucleotides: Towards in vitro selection experiments
KR20120029002A (ko) 신규한 형태의 간섭 rna 분자
CN101238213A (zh) 使用扭转嵌入核酸(TINA)稳定并选择性地形成Hoogsteen型三链体和双链体以及制备TINA的工艺